Next Article in Journal
Tomato Lycopene and Lung Cancer Prevention: From Experimental to Human Studies
Next Article in Special Issue
Differentiation Therapy of Acute Myeloid Leukemia
Previous Article in Journal
The Role of High Frequency Dynamic Threshold (HiDT) Serum Carcinoembryonic Antigen (CEA) Measurements in Colorectal Cancer Surveillance: A (Revisited) Hypothesis Paper
Previous Article in Special Issue
Targeted Therapy for Biliary Tract Cancer
Open AccessArticle

Different Aspects of Self-Reported Quality of Life in 450 German Melanoma Survivors

Institute of Cancer Epidemiology (IKE e.V.), University of Luebeck, Ratzeburger Allee 160 (Haus 50), Luebeck 23562, Germany
Association of Dermatological Prevention (ADP e.V.), Cremon 11, Hamburg 20457, Germany
Deakin University, 221 Burwood Highway, Burwood, VIC 3125, Australia
Center of Dermatology, Am Krankenhaus 1, Buxtehude 21614, Germany
Author to whom correspondence should be addressed.
Cancers 2011, 3(2), 2316-2332;
Received: 30 January 2011 / Revised: 15 April 2011 / Accepted: 28 April 2011 / Published: 11 May 2011
(This article belongs to the Special Issue Cancer Diagnosis and Targeted Therapy)
The present study was aimed at assessing quality of life (QoL) in a total of 450 melanoma patients who filled out the EORTC QLQ-C30 (Q1; 15 months post diagnosis) as part of the OVIS Study. Follow-up questionnaires (Q2) were administered two years after Q1. The analyses presented herein were based on the following assumptions: QoL of melanoma patients is worse than that of a German reference population. Further, both tumor location and tumor stage have an influence on self-reported QoL, with patients with tumors located on face, head, neck, and advanced tumor stage (T3/T4) reporting the worst QoL levels. Finally, patients’ QoL improves over time based on the theory of disease adaptation. In contrast to the above assumptions, with the exception of global health/QoL scores, differences between OVIS and the reference population were below the minimal clinical important difference of ten points. Furthermore, no clinically meaningful differences were found between patients after stratifying our data by tumor location and tumor stage. Finally, no clinically relevant changes were seen between Q1 and Q2 across all scales of the EORTC QLQ-C30. However, when data were stratified by patients with stable disease versus those with progression, clinically relevant differences were found between Q1 and Q2 predominantly in women in the latter group regarding emotional function, insomnia, dyspnoea, and fatigue. The lack of clinically meaningful differences across strata (tumor location; tumor stage), time, and patients compared to a reference population is surprising. However, it is possible that the instrument used, a generic QoL instrument, is generally not sensitive enough to detect differences in melanoma patients. Our findings may further be explained by the fact that all patients included in our sample had been diagnosed well before Q1, i.e., main illness adaptation processes may have occurred before study entry. View Full-Text
Keywords: skin neoplasms; melanoma; quality of life; population based; health care survey skin neoplasms; melanoma; quality of life; population based; health care survey
MDPI and ACS Style

Waldmann, A.; Nolte, S.; Pritzkuleit, R.; Breitbart, E.W.; Katalinic, A. Different Aspects of Self-Reported Quality of Life in 450 German Melanoma Survivors. Cancers 2011, 3, 2316-2332.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

Only visits after 24 November 2015 are recorded.
Back to TopTop